Efficacy and safety of the commercial Chinese polyherbal preparation <i>Liu Shen Wan</i> as an adjunctive treatment for herpes zoster and postherpetic neuralgia: a systematic review and meta-analysis.

ABSTRACT:

Background

Liu Shen Wan (LSW), a commercial Chinese polyherbal preparation (CCPP), is frequently utilized as an adjuvant treatment for herpes zoster and postherpetic neuralgia (HZ and PHN). Nevertheless, the clinical efficacy and safety of this treatment remain uncertain.

Purpose

This study aims to systematically evaluate the efficacy and safety of LSW as adjunctive treatment in treating HZ/PHN.

Methods

A comprehensive search was conducted across PubMed, Web of Science, Embase, Cochrane Library, ClinicalTrials.gov, and four Chinese databases. Eligibility criteria (PICOS) included the following: (1) patients with HZ/PHN; (2) LSW as adjunctive therapy (experimental group); (3) conventional treatment only (control group); (4) primary outcomes: vesicle cessation, s

SUBMITTER: Li Y 

PROVIDER: S-EPMC12698603 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature